Intuitive Surgical, Inc. (ISRG) 2024 10-K Earnings Analysis
Intuitive Surgical, Inc.2024 Earnings Analysis
85/100
Intuitive Surgical's FY2024 10-K shows $8.4B revenue, $2.3B net income, 67.5% gross margin, and 28.1% operating margin — a pure-play robotic-surgery platform operator. Zero goodwill confirms organic growth through the da Vinci installed base and Ion lung-biopsy platform. $1.3B FCF supports ongoing R&D and facilities investment; Gary Guthart served as CEO through mid-2024 with a publicly-announced transition to David Rosa (President) per the company's 2024 succession communication.
Filing analysis
Intuitive Surgical, Inc. 2024 10-K Analysis
This page reads Intuitive Surgical, Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 85/100, or grade B.
ISRG Earnings Quality
The earnings-quality module scores 90/100, with Gross Margin: 67.5%, Operating Margin: 28.1%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
ISRG Economic Moat Analysis
The moat-strength module scores 90/100, with da Vinci Install Base: Multi-generation, Recurring Revenue Model: Consumables + Services. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
ISRG Free Cash Flow vs Net Income
CF/Net Income: 1.04x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 82/100. For the diagnostic, start with cash flow vs net income.
ISRG Key Risks from the Annual Report
The risk module scores 78/100, with Competitive Entrants: Medtronic + J&J, Placement Cycle: Hospital capex. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is ISRG a High Quality Earnings Stock?
Based on this 2024 filing, ISRG passes the first screen for high-quality earnings: the overall grade is B, and the earnings-quality score is 90/100. This is a research screen, not investment advice.
Read the report first
Understand Intuitive Surgical, Inc. first, then decide if it belongs on your watchlist
The ISRG score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep ISRG with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the ISRG report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 67.5% reflects the razor-and-blade business model — da Vinci system sales, recurring procedure-based instruments and accessories consumables, and service contracts each with different margin profiles disclosed in the segment footnote.
Per the FY2024 10-K income statement, operating margin of 28.1% reflects the mature-product-plus-scale platform economics. Procedures volume (robotic-surgery-procedure count disclosed in quarterly investor materials) is the principal driver of consumables-and-service recurring revenue.
Per the FY2024 cash flow statement, OCF of $2.4B is 1.04x net income of $2.3B — a tight conversion reflecting the straightforward accounting profile with limited non-cash distortion.
Per the FY2024 quarterly-procedure-metric disclosures and MD&A, global da Vinci procedure volume has grown across US and international markets. The procedure-volume KPI is the principal leading indicator disclosed in supplemental investor tables.
Earnings quality scores 90/100. Per the FY2024 10-K, Intuitive Surgical's $8.4B revenue produces a 67.5% gross margin, 28.1% operating margin, and 1.04x CF/NI ratio — the profile of a mature platform operator with a mix of system sales, procedure-recurring consumables, and service contracts. Procedure-volume growth disclosed in quarterly investor metrics drives the recurring-revenue-weighted mix.
Moat Strength
Per the FY2024 10-K installed-base disclosures, the global da Vinci system base has grown across successive generations (da Vinci Xi, X, SP for single-port procedures, and the new da Vinci 5 launched in 2024 per the FDA-clearance press release). Hospital switching costs include capital-equipment amortization, surgeon-training reinvestment, and workflow integration.
Per the FY2024 revenue-mix disclosures, a meaningful portion of revenue comes from per-procedure instruments and accessories (recurring consumables) plus service contracts on the installed base. Management publicly describes the recurring-revenue share in investor-day materials.
Per the FY2024 Ion-specific disclosures, Ion is the robotic-assisted lung-biopsy platform addressing lung-cancer-diagnostic use cases. Procedure-growth metrics for Ion are disclosed in the quarterly supplemental investor tables.
Per the FY2024 balance sheet, goodwill is effectively zero — Intuitive has grown principally organically rather than via M&A-driven platform consolidation. No material acquisition-impairment exposure.
Moat strength scores 90/100. Per the FY2024 10-K, Intuitive Surgical's competitive position rests on (1) the da Vinci multi-generation installed base (Xi, X, SP, and the 2024-launched da Vinci 5 per the FDA-clearance press release) with hospital-switching-cost protection, (2) the recurring-revenue model from per-procedure instruments-and-accessories consumables plus service contracts, (3) the Ion lung-biopsy platform as an adjacent robotic platform extension, and (4) zero goodwill confirming organic-growth discipline.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $1.3B (OCF $2.4B minus capex $1.1B) reflects the current investment cycle in manufacturing capacity and new-platform development.
$1.1B capex on $8.4B revenue equals 13.2% — elevated versus mature-medical-device peer averages, reflecting disclosed manufacturing-capacity expansion supporting the da Vinci 5 launch and Ion platform ramp.
Per the FY2024 10-K capital-return section, Intuitive does not pay a regular dividend. Capital return is channeled through share repurchases per the disclosed program; the policy reflects management's publicly-framed reinvestment-in-R&D-and-manufacturing priority.
Per the FY2024 balance sheet, cash and investments substantially exceed debt (no material long-term debt per the debt-schedule footnote). The net-cash balance sheet provides strategic optionality without refinancing-risk exposure.
Capital allocation scores 82/100. Per the FY2024 10-K, $1.3B FCF reflects the current elevated-capex investment cycle (13.2% capex/revenue) tied to manufacturing-capacity expansion supporting the da Vinci 5 launch. Intuitive does not pay a dividend — capital return runs through share repurchases per the capital-return disclosure. The net-cash balance sheet provides strategic flexibility without debt-service constraints.
Key Risks
Per the FY2024 Risk Factors and industry trade-press coverage, robotic-surgery platform competition includes Medtronic's Hugo RAS (disclosed via Medtronic product-launch communications), Johnson & Johnson's Ottava (under development per JNJ's investor-day materials), and CMR Surgical's Versius. Competitive response is tracked in FDA-clearance and commercial-launch communications.
Per the FY2024 placement-metric disclosures, new da Vinci system placements depend on hospital capital-budget cycles. Hospital-financial-pressure periods compress new-placement cadence — a disclosed industry-wide sensitivity.
Per the FY2024 Risk Factors, Intuitive's revenue concentrates on the da Vinci robotic-surgery platform (plus the smaller Ion contribution). Platform-specific regulatory, reimbursement, or competitive developments could materially affect consolidated revenue.
Per the FY2024 international-revenue disclosures, international growth (including China via the joint venture and EU markets) is a disclosed strategic priority. Country-specific reimbursement and regulatory conditions affect the international-placement trajectory.
Risk profile scores 78/100 (higher = safer). Per the FY2024 10-K, the main watch-items are (1) competitive entrants including Medtronic Hugo RAS, J&J Ottava, and CMR Surgical Versius tracked via product-launch and FDA-clearance communications, (2) new-placement dependency on hospital capital-budget cycles, (3) platform-concentration risk around the da Vinci franchise, and (4) international-expansion conditions in China JV and EU markets.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.